KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Gilead Sciences (GILD) R&D In Process (2019 - 2026)

Gilead Sciences filings provide 7 years of R&D In Process readings, the most recent being $80.0 million for Q4 2025.

  • On a quarterly basis, R&D In Process rose 827.27% to $80.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $564.0 million, a 87.27% decrease, with the full-year FY2025 number at $1.0 billion, down 78.04% from a year prior.
  • R&D In Process hit $80.0 million in Q4 2025 for Gilead Sciences, down from $170.0 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $3.9 billion in Q1 2024 to a low of -$11.0 million in Q4 2024.
  • Median R&D In Process over the past 5 years was $148.0 million (2021), compared with a mean of $372.4 million.
  • Biggest five-year swings in R&D In Process: surged 2550.0% in 2023 and later crashed 110.89% in 2024.
  • Gilead Sciences' R&D In Process stood at $669.0 million in 2021, then crashed by 76.38% to $158.0 million in 2022, then plummeted by 36.08% to $101.0 million in 2023, then crashed by 110.89% to -$11.0 million in 2024, then soared by 827.27% to $80.0 million in 2025.
  • The last three reported values for R&D In Process were $80.0 million (Q4 2025), $170.0 million (Q3 2025), and $61.0 million (Q2 2025) per Business Quant data.